110 related articles for article (PubMed ID: 38812296)
1. Brexpiprazole Prevents the Malignant Progression of Human Colorectal Cancer Cells and Increases Its Sensitivity to EGFR Inhibition.
Long X; Liu X; Xia W; Liu L; Chen W
Front Biosci (Landmark Ed); 2024 May; 29(5):174. PubMed ID: 38812296
[TBL] [Abstract][Full Text] [Related]
2. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
3. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
4. Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
Liu BS; Xia HW; Zhou S; Liu Q; Tang QL; Bi NX; Zhou JT; Gong QY; Nie YZ; Bi F
Oncol Rep; 2018 Oct; 40(4):2171-2182. PubMed ID: 30106444
[TBL] [Abstract][Full Text] [Related]
5. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
6. miR-145-5p restrained cell growth, invasion, migration and tumorigenesis via modulating RHBDD1 in colorectal cancer via the EGFR-associated signaling pathway.
Niu Y; Zhang J; Tong Y; Li J; Liu B
Int J Biochem Cell Biol; 2019 Dec; 117():105641. PubMed ID: 31693935
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer.
Zulkifli A; Tan FH; Areeb Z; Stuart SF; Gomez J; Paradiso L; Luwor RB
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281166
[TBL] [Abstract][Full Text] [Related]
9. A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2X7 receptor.
Zhang Y; Li F; Wang L; Lou Y
Biochem Biophys Res Commun; 2021 Jun; 558():147-153. PubMed ID: 33915328
[TBL] [Abstract][Full Text] [Related]
10. Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer.
Sanomachi T; Suzuki S; Togashi K; Seino S; Yoshioka T; Kitanaka C; Okada M; Yamamoto M
Anticancer Res; 2019 Sep; 39(9):4817-4828. PubMed ID: 31519584
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
12. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
13. Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells.
Shigeta K; Hayashida T; Hoshino Y; Okabayashi K; Endo T; Ishii Y; Hasegawa H; Kitagawa Y
PLoS One; 2013; 8(6):e66302. PubMed ID: 23824671
[TBL] [Abstract][Full Text] [Related]
14. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
[TBL] [Abstract][Full Text] [Related]
15. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
[No Abstract] [Full Text] [Related]
16. Combination effect of cetuximab with radiation in colorectal cancer cells.
Shin HK; Kim MS; Lee JK; Lee SS; Ji YH; Kim JI; Jeong JH
Tumori; 2010; 96(5):713-20. PubMed ID: 21302618
[TBL] [Abstract][Full Text] [Related]
17. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
[TBL] [Abstract][Full Text] [Related]
18. NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer.
Yang G; Huang L; Jia H; Aikemu B; Zhang S; Shao Y; Hong H; Yesseyeva G; Wang C; Li S; Sun J; Zheng M; Ma J
Oncogene; 2021 Oct; 40(41):5993-6006. PubMed ID: 34385595
[TBL] [Abstract][Full Text] [Related]
19. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
20. Cucurbitacin B controls M2 macrophage polarization to suppresses metastasis via targeting JAK-2/STAT3 signalling pathway in colorectal cancer.
Zhang H; Zhao B; Wei H; Zeng H; Sheng D; Zhang Y
J Ethnopharmacol; 2022 Apr; 287():114915. PubMed ID: 34954267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
